JOAN ALTMAN: Open Payments
NPI 1134239080 · CHANDLER, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,009 in 116 payments from 21 companies in 2025. Trend: 2023 $3,300 · 2024 $3,529 · 2025 $3,009
Food & beverage: $2,928Education: $81
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 11 | $469 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 11 | $304 |
| Incyte Corporation | 9 | $268 |
| GENZYME CORPORATION | 8 | $253 |
| Novartis Pharmaceuticals Corporation | 8 | $249 |
| ABBVIE INC. | 11 | $198 |
| Amgen Inc. | 6 | $190 |
| Janssen Biotech, Inc. | 7 | $183 |
| UCB, Inc. | 7 | $158 |
| Lilly USA, LLC | 7 | $118 |
Products named: DUPIXENT, OPZELURA, Winlevi, OTEZLA, TREMFYA, COSENTYX, Bimzelx, SKYRIZI.
Industry payments across AZ — which companies pay providers there.
